Sylvester Comprehensive Cancer Center

  • G040554 - Alderuccio, Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180681

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40554: A Phase I/II Trial Of Mosunetuzumab (BTCT4465A) As Consolidation Therapy In Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy And As Therapy In Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable To Tolerate Full-Dose Chemotherapy

    Eligibility Criteria - NCT03677154 *This information has been extracted from " www.clinicaltrials.gov"

  • RP6530+Romidepsin-1805 - Alderuccio, Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:
    RCemailImg Katherine Narvaez-Camacho
    RCphone 3052438063

    IRB: 20181179

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: RPS

    Enrolling Sites:

    Sylvester

    Title:

    RP6530+Romidepsin-1805: An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K d/┐ dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma

    Eligibility Criteria - NCT03770000 *This information has been extracted from " www.clinicaltrials.gov"

  • REGN5458 - Alderuccio, Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20190220

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: REGENERON PHARM INC

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

    Eligibility Criteria - NCT03761108 *This information has been extracted from " www.clinicaltrials.gov"

  • LOXO-BTK-18001 - Alencar, Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20190647

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Lymphoid Leukemia,Leukemia, Other

    Sponsor: LOXO ONCOLOGY

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Eligibility Criteria - NCT03740529 *This information has been extracted from " www.clinicaltrials.gov"

  • X15015 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20170602

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    X15015: A Phase I Trial of Pevonedistat in combination with VXLD chemotherapy for adolescent and young adults with relapsed/refractory Acute Lymphoblastic Leukemia

    Eligibility Criteria - NCT03349281 *This information has been extracted from " www.clinicaltrials.gov"

  • M16-802 - Bradley, Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180388

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: ABBVIE

    Enrolling Sites:

    Sylvester

    Title:

    M16-802: A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

    Eligibility Criteria - NCT03625505 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190961 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20190961

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Other Hematopoietic

    Sponsor: FORTY SEVEN, INC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies

    Eligibility Criteria - NCT03248479 *This information has been extracted from " www.clinicaltrials.gov"

  • DCC-2618-01-001 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20170452

    SDG: Neurological Cancer
    Disease Site(s):

    Esophagus,Brain and Nervous System,Other Hematopoietic,Stomach,Small Intestine,Colon,Rectum,Other Digestive Organ

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    DCC-2618-01-001: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety,Tolerability, Efficacy, and Pharmacokinetics in Patients with AdvancedMalignancies

    Eligibility Criteria - NCT02571036 *This information has been extracted from " www.clinicaltrials.gov"

  • PT2977-101 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20170815

    SDG: Neurological Cancer
    Disease Site(s):

    Kidney,Brain and Nervous System

    Sponsor: Peloton

    Enrolling Sites:

    Sylvester

    Title:

    PT2977-101: A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2a Inhibitor, in Patients With Advanced Solid Tumors

    Eligibility Criteria - NCT02974738 *This information has been extracted from " www.clinicaltrials.gov"

  • 2102-ONC-102 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone 3052438173

    IRB: 20180721

    SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System,Pancreas,Bones and Joints,Soft Tissue

    Sponsor: FORMA

    Enrolling Sites:

    Sylvester

    Title:

    2102-ONC-102: A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

    Eligibility Criteria - NCT03684811 *This information has been extracted from " www.clinicaltrials.gov"

  • AFPc332T - Feun, Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20160692

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Liver

    Sponsor: Adaptimmune

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced epatocellular Carcinoma (HCC)

    Eligibility Criteria - NCT03132792 *This information has been extracted from " www.clinicaltrials.gov"

  • ADP-0011:008 - Hoffman, James

  • Investigator:
    James Hoffman
    RCname Email

    Coordinator:
    RCemailImg Micaela Martinez
    RCphone 3052439731

    IRB: 20170613

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    ADP-0011-008: Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1A Positive Relapsed and Refractory Multiple Myeloma

    Eligibility Criteria - NCT03168438 *This information has been extracted from " www.clinicaltrials.gov"

  • SGNBCMA-001 - Hoffman, James

  • Investigator:
    James Hoffman
    RCname Email

    Coordinator:
    RCemailImg Katherine Narvaez-Camacho
    RCphone 3052438063

    IRB: 20180619

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SEATTLE GENETICS

    Enrolling Sites:

    Sylvester

    Title:

    SGNBCMA-001: A Phase 1 Study of SEA-BCMA in Patients With Relapsed Or Refractory Multiple Myeloma

    Eligibility Criteria - NCT03582033 *This information has been extracted from " www.clinicaltrials.gov"

  • C-610-01 - Hosein, Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20180763

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Breast,Bladder,Rectum,Soft Tissue,Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-610-01:A Phase 1a First-in-Human Study of Safety and Tolerability of ASV? AGEN2017 With QS-21 Stimulon« Adjuvant as a Single Agent in Subjects with Solid Tumor at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection

    Eligibility Criteria - NCT03673020 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin

    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • AGEN2034 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170076

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Cervix Uteri

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-700-01: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

    Eligibility Criteria - NCT03104699 *This information has been extracted from " www.clinicaltrials.gov"

  • AL3818-US-002 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Michelle Munevar
    RCphone 3052437530

    IRB: 20170218

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary

    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    AL3818-US-002: A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma

    Eligibility Criteria - NCT02584478 *This information has been extracted from " www.clinicaltrials.gov"

  • C-550-01 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Antonio Marrero

    IRB: 20181020

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri

    Sponsor: Agenus

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    C-550-01: A Phase 1/2 Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

    Eligibility Criteria - NCT03495882 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190823 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20190823

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Ovary,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Lung

    Sponsor: Plexxikon

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies

    Eligibility Criteria - NCT03297424 *This information has been extracted from " www.clinicaltrials.gov"

  • BTCRC-LUN17-127 - Ikpeazu, Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20181092

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: BTCRC

    Enrolling Sites:

    Sylvester

    Title:

    BTCRC-LUN17-127 : A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127

    Eligibility Criteria - NCT03575793 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180752 - Levitt Roy

  • Investigator:
    Roy Levitt
    RCname Email

    Coordinator:

    IRB: 20180752

    SDG: Other
    Disease Site(s):

    Multiple

    Sponsor: SORR

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated with Cancer

    Eligibility Criteria - NCT03226574 *This information has been extracted from " www.clinicaltrials.gov"

  • IM-202 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20180968

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Stomach,Lung

    Sponsor: IAB

    Enrolling Sites:

    Sylvester

    Title:

    IM-202 : A Randomized, Open-Label, Multicenter, Phase 1b/2 Trial Evaluating The Safety And Efficacy Of Intratumorally-Administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who are Candidates ForCPI Therapy

    Eligibility Criteria - NCT03735290 *This information has been extracted from " www.clinicaltrials.gov"

  • TAB001-01 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:

    IRB: 20190182

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Other Endocrine System,Colon

    Sponsor: TABS

    Enrolling Sites:

    Sylvester

    Title:

    TAB001-01: tle ICMJEA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies

    Eligibility Criteria - NCT03474640 *This information has been extracted from " www.clinicaltrials.gov"

  • 1381.2 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190219

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Bladder,Stomach,Lung

    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Sylvester

    Title:

    1381.2: An Open Label, Phase I Dose-Finding Study Of BI 754111 In Combination With BI 754091 In Patients With Advanced Solid Cancers Followed By Expansion Cohorts At The Selected Dose Of The Combination In Patients With Non-Small Cell Lung Cancer And Other Solid Tumors

    Eligibility Criteria - NCT03156114 *This information has been extracted from " www.clinicaltrials.gov"

  • BLU-667-1101 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170957

    SDG: Thoracic Oncology
    Disease Site(s):

    Thyroid,Other Endocrine System,Colon,Lung

    Sponsor: Blueprint Medicines

    Enrolling Sites:

    Sylvester

    Title:

    BLU-667-1101: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

    Eligibility Criteria - NCT03037385 *This information has been extracted from " www.clinicaltrials.gov"

  • 208471 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:
    RCemailImg Maria Pardo
    RCphone 3052437036

    IRB: 20180862

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    208471: A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer

    Eligibility Criteria - NCT03709706 *This information has been extracted from " www.clinicaltrials.gov"

  • LYMRIT-37-05 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20160851

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Lymphoid Leukemia

    Sponsor: Nordic

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 Dose finding study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin«) in patients with relapsed, diffuse large B-cell lymphoma, not eligible for autologous stem cell transplant

    Eligibility Criteria - NCT02658968 *This information has been extracted from " www.clinicaltrials.gov"

  • GSK3326595 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180040

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Breast,Brain and Nervous System,Non-Hodgkin Lymphoma

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    GSK204653: A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

    Eligibility Criteria - NCT02783300 *This information has been extracted from " www.clinicaltrials.gov"

  • ACE-LY-003 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180457

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Acerta

    Enrolling Sites:

    Sylvester

    Title:

    ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT02180711 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40516 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180637

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40516:An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, and Efficacy Of Mosunetuzumab (BTCT4465A) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma Lymphoma

    Eligibility Criteria - NCT03671018 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40515 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180638

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40515: A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating The Safety, Tolerability, Pharmacokinetics, And Efficacy OfMosunetuzumab (BTCT4465) In Combination With CHOP or CHP-PolatuzumabVedotin In Patients With B-Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT03677141 *This information has been extracted from " www.clinicaltrials.gov"

  • VYR-VSV2-101 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20170023

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Lung,Melanoma, skin,Kaposis sarcoma

    Sponsor: VYRIAD

    Enrolling Sites:

    Sylvester

    Title:

    Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFN▀-NIS), in Patients with Refractory Solid Tumors

    Eligibility Criteria - NCT02923466 *This information has been extracted from " www.clinicaltrials.gov"

  • SGN22E-002 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20170918

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Other Urinary

    Sponsor: SEATTLE GENETICS

    Enrolling Sites:

    Sylvester

    Title:

    SGN22E-002: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for thetreatment of urothelial cancer

    Eligibility Criteria - NCT03288545 *This information has been extracted from " www.clinicaltrials.gov"

  • JX594-REN026 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20180055

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Kidney

    Sponsor: SILLAJEN INC

    Enrolling Sites:

    Sylvester

    Title:

    JX594-REN026: A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti-PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)

    Eligibility Criteria - NCT03294083 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Colon,Breast-Female,Melanoma, skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • TTX-030-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20181017

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Colon,Pancreas

    Sponsor: TTH

    Enrolling Sites:

    Sylvester

    Title:

    TTX-030-001 : Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy inPatients with Lymphoma or Solid Tumor Malignancies

    Eligibility Criteria - NCT03884556 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-444-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190073

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate,Bladder,Kidney,Liver

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-444-001: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

    Eligibility Criteria - NCT02655822 *This information has been extracted from " www.clinicaltrials.gov"

  • C-500-01 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160238

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Brain and Nervous System,Leukemia, Other,Bones and Joints,Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-500-01

    Eligibility Criteria - NCT02694822 *This information has been extracted from " www.clinicaltrials.gov"

  • AST-008-102 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20180957

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Bones and Joints,Melanoma, skin

    Sponsor: EXICURE INC

    Enrolling Sites:

    Sylvester

    Title:

    AST-008-102 :A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

    Eligibility Criteria - NCT03684785 *This information has been extracted from " www.clinicaltrials.gov"

  • ATA129-NPC-202 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone 3052430124

    IRB: 20181013

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: Atara

    Enrolling Sites:

    Sylvester

    Title:

    ATA129-NPC-202 : An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinum-pretreated, Recurrent/Metastatic Epstein Barr Virus Associated Nasopharyngeal Carcinoma

    Eligibility Criteria - NCT03769467 *This information has been extracted from " www.clinicaltrials.gov"

  • C3851001 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190114

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Cervix Uteri,Other Endocrine System,Lung

    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester

    Title:

    C3851001: A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics Of Escalating Doses Of PF-06939999 (Prmt5 Inhibitor) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, CervicalCancer And Bladder Cancer

    Eligibility Criteria - NCT03854227 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-101 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:
    RCemailImg Leanne Rodriguez
    RCphone 3052432383

    IRB: 20180056

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    AMC-101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas A Trial of the AIDS Malignancy Consortium (AMC)

    Eligibility Criteria - NCT03220022 *This information has been extracted from " www.clinicaltrials.gov"

  • EMR100036-002 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160382

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Breast,Cervix Uteri,Stomach,Lung

    Sponsor: EMD

    Enrolling Sites:

    Sylvester

    Title:

    An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT02516813 *This information has been extracted from " www.clinicaltrials.gov"

  • LUD2015-008 - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170230

    SDG: Gynecologic Cancer
    Disease Site(s):

    Ovary,Colon,Rectum

    Sponsor: LUDWIG INSTITUTE FOR CANCER RESEARCH

    Enrolling Sites:

    Sylvester

    Title:

    LUD2015-008: A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies

    Eligibility Criteria - NCT02963831 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180880 - Sussman Daniel

  • Investigator:
    Daniel Sussman
    RCname Email

    Coordinator:

    IRB: 20180880

    SDG: Colorectal Cancer
    Disease Site(s):

    Colon

    Sponsor: Janssen

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis

    Eligibility Criteria - NCT03649971 *This information has been extracted from " www.clinicaltrials.gov"

  • DS8201-a-U105 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20180855

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Bladder

    Sponsor: DAIICHI SANKYO

    Enrolling Sites:

    Sylvester

    Title:

    DS8201-A-U105:A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer

    Eligibility Criteria - NCT03523572 *This information has been extracted from " www.clinicaltrials.gov"

  • 1280.18 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20181019

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Sylvester

    Title:

    1280.18 : An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts

    Eligibility Criteria - NCT03099174 *This information has been extracted from " www.clinicaltrials.gov"

  • ATTCK-34-01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20190286

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: UNUM THERAPEUTICS

    Enrolling Sites:

    Sylvester

    Title:

    ATTCK-34-01: A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

    Eligibility Criteria - NCT03680560 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190673 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190673

    SDG: Breast Cancer
    Disease Site(s):

    Esophagus,Breast,Ovary,Other Female Genital,Kidney,Stomach,Colon,Lung

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"

  • FORMA 2102-HEM-101 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20160327

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified

    Sponsor: FORMA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

    Eligibility Criteria - NCT02719574 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180054 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180054

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination with Low Dose Cytarabine (LDAC) in Adult Patients with Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS)

    Eligibility Criteria - NCT03459859 *This information has been extracted from " www.clinicaltrials.gov"

  • M16-186 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180197

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: ABBVIE

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Eligibility Criteria - NCT03441555 *This information has been extracted from " www.clinicaltrials.gov"

  • IMG-7289 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20180198

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other

    Sponsor: Imago

    Enrolling Sites:

    Sylvester

    Title:

    A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis.

    Eligibility Criteria - NCT03136185 *This information has been extracted from " www.clinicaltrials.gov"

  • 208809 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180677

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    208809: A Phase I/II Study To Investigate The Safety And Clinical Activity Of GSK3326595 And Other Agents In Subjects With Myelodysplastic Syndrome And Acute Myeloid Leukaemia.

    Eligibility Criteria - NCT03614728 *This information has been extracted from " www.clinicaltrials.gov"

  • 5001 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20180739

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other

    Sponsor: Aptevo Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    5001:Phase 1/1b Open-Label, Dose-Escalation Study of APVO436 in Patients with Relapsed or Refractory AML or High-Grade MDS

    Eligibility Criteria - NCT03647800 *This information has been extracted from " www.clinicaltrials.gov"

  • KTE-C19-104 - Ziga, Edward

  • Investigator:
    Edward Ziga
    RCname Email

    Coordinator:

    IRB: 20160129

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: Kite

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)

    Eligibility Criteria - NCT02625480 *This information has been extracted from " www.clinicaltrials.gov"